Publications by authors named "Flamant Mathurin"

Claim this Profile
C
Clinical Trial: Simplified Bowel Preparation for Small Bowel Capsule Endoscopy in Crohn's Disease.
Raphaëlle Rouveyre, Sandrine Coudol, Michael Collins, Astrid de Maissin, Mathurin Flamant

Aliment Pharmacol Ther· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discordance between patients' perception and endoscopic assessment of disease activity in ulcerative colitis.
Boilève Juliette, Trang-Poisson Caroline, Flamant Mathurin, Bouguen Guillaume, Goronflot Thomas

Therap Adv Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, Mathurin Flamant

Drugs Real World Outcomes· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Evidence of Clinical Outcomes of the Use of the Adalimumab Biosimilar SB5 in Rheumatic and Gastrointestinal Immune-Mediated Inflammatory Diseases: 12-Month Data from the PERFUSE Study.
Bruno Fautrel, Yoram Bouhnik, Carine Salliot, Franck Carbonnel, Mathurin Fumery, Mathurin Flamant

Drugs Real World Outcomes· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Confocal laser endomicroscopy as predictive biomarker of clinical and endoscopic efficacy of vedolizumab in ulcerative colitis: The DETECT study.
Lucille Quénéhervé, Caroline Trang-Poisson, Aurélie Fantou, Mathurin Flamant, Tony Durand

PLoS One· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The PERFUSE study: The experience of patients receiving Adalimumab biosimilar SB5.
Yoram Bouhnik, Franck Carbonnel, Mathurin Fumery, Mathurin Flamant, Anne Buisson

Dig Liver Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Acceptability of Therapeutic Maintenance Regimens in Patients With Inflammatory Bowel Disease: Results From the Nationwide ACCEPT2 Study.
Anthony Buisson, Mélanie Serrero, Laurie Orsat, Stéphane Nancey, Pauline Rivière, Mathurin Flamant, Mathurin Fumery

Inflamm Bowel Dis· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis" [EBioMedicine 49 (2019) 172-188].
Simon Valès, Gregory Bacola, Mandy Biraud, Mélissa Touvron, Anne Bessard, Mathurin Flamant

EBioMedicine· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Cassandra Rayer, Maria Nachury, Arnaud Bourreille, Xavier Roblin, Laurent Peyrin-Biroulet, Mathurin Flamant, Mathurin Fumery

BMC Gastroenterol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Cassandra Rayer, Maria Nachury, Arnaud Bourreille, Xavier Roblin, Laurent Peyrin-Biroulet, Mathurin Flamant, Mathurin Fumery

BMC Gastroenterol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study.
Marc Ferrante, Anja Schirbel, Marieke J Pierik, Thomas Haas, Mathurin Flamant

Eur J Gastroenterol Hepatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multi-expert annotation of Crohn's disease images of the small bowel for automatic detection using a convolutional recurrent attention neural network.
Astrid de Maissin, Remi Vallée, Mathurin Flamant, Marie Fondain-Bossiere, Catherine Le Berre

Endosc Int Open· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VALIDation of the IBD-Disk Instrument for Assessing Disability in Inflammatory Bowel Diseases in a French Cohort: The VALIDate Study.
Catherine Le Berre, Mathurin Flamant, Guillaume Bouguen, Laurent Siproudhis, Marie Dewitte

J Crohns Colitis· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Treatment of Internal Fistulizing Crohn's Disease.
Guillaume Bouguen, Audrey Huguet, Aurélien Amiot, Stéphanie Viennot, Franck Cholet, Mathurin Flamant

Clin Gastroenterol Hepatol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cells hijack enteric glia to activate colon cancer stem cells and stimulate tumorigenesis.
Simon Valès, Gregory Bacola, Mandy Biraud, Mélissa Touvron, Anne Bessard, Mathurin Flamant

EBioMedicine· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proactive Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.
Xavier Roblin, Pauline Riviere, Mathurin Flamant, Pauline Veyrard, Fabien Poullenot

Inflamm Bowel Dis· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DIAMOND study: an additional evidence of the interest of being proactive in IBD.
Xavier Roblin, Mathurin Flamant

Ann Transl Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflammatory bowel disease: towards a personalized medicine.
Mathurin Flamant, Xavier Roblin

Therap Adv Gastroenterol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Acceptability and Perceived Clinical Utility of Monitoring Tools: A Nationwide Survey of Patients with Inflammatory Bowel Disease.
Anthony Buisson, Florent Gonzalez, Florian Poullenot, Stéphane Nancey, Elisa Sollellis, Mathurin Fumery, Mathurin Flamant

Inflamm Bowel Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Golimumab for the treatment of ulcerative colitis.
Mathurin Flamant, Stephane Paul, Xavier Roblin

Expert Opin Biol Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Mathurin Flamant, Josselin Rigaill, Stephane Paul, Xavier Roblin

Drugs· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
Yael Abitbol, David Laharie, Jacques Cosnes, Matthieu Allez, Stéphane Nancey, Mathurin Fumery, Mathurin Flamant

J Crohns Colitis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Could therapeutic drug monitoring of anti-TNF-α be useful to consider a de-escalation of treatment?
Mathurin Flamant, Xavier Roblin

Expert Opin Biol Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease.
Sylvie Rajca, Virginie Grondin, Edouard Louis, Gwenola Vernier-Massouille, Jean-Charle Grimaud, Mathurin Flamant

Inflamm Bowel Dis· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prevalence and outcome of jejunal lesions visualized by small bowel capsule endoscopy in Crohn's disease.
Mathurin Flamant, Caroline Trang, Olivier Maillard, Sylvie Sacher-Huvelin, Marc Le Rhun

Inflamm Bowel Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis